Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT

• Status: Terminated
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

To compare the livebirth rate of women with recurrent pregnancy loss and autoantibodies randomized to either low molecular weight heparin plus aspirin versus aspirin alone.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mount Sinai Hospital, Canada
• Collaborators: Canadian Institutes of Health Research (CIHR); Pfizer
• Treatments: Aspirin; Calcium heparin; Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Tinzaparin

Criteria

Inclusion Criteria:

• history of two or more unexplained consecutive pregnancy losses prior to 32 weeks

• presence of one of the panel of autoantibodies/thrombophilia markers

• confirmed pregnancy

Exclusion Criteria:

• SLE

• known peptic ulcer disease

• sensitivity to ASA or heparin

• previous thrombotic event

• geographic distance from clinic

• failure to consent